NASDAQ:CARM Carisma Therapeutics (CARM) Stock Forecast, Price & News $4.23 -0.25 (-5.58%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$4.13▼$4.6250-Day Range$3.94▼$7.8552-Week Range$2.75▼$13.00Volume263,076 shsAverage Volume244,886 shsMarket Capitalization$170.38 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Carisma Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside136.4% Upside$10.00 Price TargetShort InterestBearish13.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.59) to ($2.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector470th out of 970 stocksPharmaceutical Preparations Industry211th out of 448 stocks 3.5 Analyst's Opinion Consensus RatingCarisma Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Carisma Therapeutics has a forecasted upside of 136.4% from its current price of $4.23.Amount of Analyst CoverageCarisma Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.92% of the float of Carisma Therapeutics has been sold short.Short Interest Ratio / Days to CoverCarisma Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Carisma Therapeutics has recently decreased by 8.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCarisma Therapeutics does not currently pay a dividend.Dividend GrowthCarisma Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CARM. Previous Next 3.6 News and Social Media Coverage News SentimentCarisma Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Carisma Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CARM on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows4 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.00% of the stock of Carisma Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 32.22% of the stock of Carisma Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Carisma Therapeutics are expected to grow in the coming year, from ($2.59) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Carisma Therapeutics is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Carisma Therapeutics is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCarisma Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Carisma Therapeutics (NASDAQ:CARM) StockCarisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.Read More CARM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CARM Stock News HeadlinesSeptember 6, 2023 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About CARISMA TherapeuticsSeptember 5, 2023 | finance.yahoo.comCarisma Therapeutics to Present at Upcoming Investor ConferencesOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 1, 2023 | finance.yahoo.comCarisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR SummitAugust 23, 2023 | msn.comWall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should KnowAugust 23, 2023 | finance.yahoo.comWall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should KnowAugust 13, 2023 | finance.yahoo.comCarisma Therapeutics Second Quarter 2023 Earnings: Beats ExpectationsAugust 11, 2023 | nasdaq.comHC Wainwright & Co. Maintains Carisma Therapeutics (CARM) Buy RecommendationOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 11, 2023 | markets.businessinsider.comAnalyst Ratings for CARISMA TherapeuticsAugust 10, 2023 | finance.yahoo.comCarisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 10, 2023 | finanznachrichten.deCarisma Therapeutics Inc.: Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 1, 2023 | msn.comCarisma Therapeutics (CARM) Price Target Increased by 8.33% to 9.95July 19, 2023 | finance.yahoo.comPublic companies own 19% of Carisma Therapeutics, Inc. (NASDAQ:CARM) shares but retail investors control 43% of the companyJuly 7, 2023 | msn.comEvercore ISI Group Initiates Coverage of Carisma Therapeutics (CARM) with Outperform RecommendationJune 30, 2023 | msn.comHC Wainwright & Co. Reiterates Carisma Therapeutics (CARM) Buy RecommendationJune 30, 2023 | msn.comBaird Reiterates Carisma Therapeutics (CARM) Outperform RecommendationJune 29, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Carisma Therapeutics (CARM)June 28, 2023 | finance.yahoo.comCarisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid TumorsJune 26, 2023 | msn.comCarisma Therapeutics to join the Russell 2000, Russell 3000 and Russell Microcap indexesJune 26, 2023 | finance.yahoo.comCarisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® IndexesJune 14, 2023 | finance.yahoo.comCarisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human ResourcesJune 8, 2023 | finance.yahoo.comCarisma Therapeutics (NASDAQ:CARM) Is In A Good Position To Deliver On Growth PlansJune 5, 2023 | finance.yahoo.comCarisma Therapeutics to Present at Upcoming Investor Conferences in June 2023May 31, 2023 | msn.comCarisma Therapeutics Shines on New Cancer TreatmentMay 30, 2023 | finance.yahoo.comCarisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023May 24, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Carisma Therapeutics (CARM) with Buy RecommendationSee More Headlines Receive CARM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CARM Company Calendar Last Earnings8/10/2023Today10/01/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CARM CUSIPN/A CIK1485003 WebN/A Phone617-444-8550Fax617-858-0911EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+136.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,880,000.00 Net MarginsN/A Pretax Margin-612.60% Return on Equity-19.32% Return on Assets-13.56% Debt Debt-to-Equity Ratio0.01 Current Ratio6.80 Quick Ratio6.80 Sales & Book Value Annual Sales$40 million Price / Sales4.26 Cash Flow$3.71 per share Price / Cash Flow1.14 Book Value$15.60 per share Price / Book0.27Miscellaneous Outstanding Shares40,280,000Free Float33,437,000Market Cap$170.38 million OptionableNot Optionable Beta0.86 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Steven Kelly (Age 58)Pres, CEO & Director Comp: $666kMr. Michael Klichinsky Ph.D. (Age 33)Pharm.D., PharmD, Co-Founder & Chief Scientific Officer Comp: $469kMr. Richard S. Morris CPA (Age 49)CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off. Comp: $570kMr. Saar Gill M.D.Ph.D., Co-FounderMr. Eric H. Siegel J.D. (Age 58)MBA, Gen. Counsel & Corp. Sec. Ms. Terry ShieldsSr. VP of HRMr. Tom Wilton (Age 49)Chief Bus. Officer More ExecutivesKey CompetitorsSelecta BiosciencesNASDAQ:SELBVaxxinityNASDAQ:VAXXEmergent BioSolutionsNYSE:EBSImmutepNASDAQ:IMMPStoke TherapeuticsNASDAQ:STOKView All CompetitorsInstitutional OwnershipBarclays PLCBought 5,312 shares on 9/21/2023Ownership: 0.013%California State Teachers Retirement SystemBought 8,869 shares on 8/21/2023Ownership: 0.022%Nuveen Asset Management LLCBought 99,788 shares on 8/16/2023Ownership: 0.248%Goldman Sachs Group Inc.Bought 27,677 shares on 8/15/2023Ownership: 0.069%Wells Fargo & Company MNBought 10,083 shares on 8/15/2023Ownership: 0.026%View All Institutional Transactions CARM Stock - Frequently Asked Questions Should I buy or sell Carisma Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Carisma Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CARM shares. View CARM analyst ratings or view top-rated stocks. What is Carisma Therapeutics' stock price forecast for 2023? 4 equities research analysts have issued 12-month target prices for Carisma Therapeutics' stock. Their CARM share price forecasts range from $7.00 to $12.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 136.4% from the stock's current price. View analysts price targets for CARM or view top-rated stocks among Wall Street analysts. How have CARM shares performed in 2023? Carisma Therapeutics' stock was trading at $3.25 at the beginning of the year. Since then, CARM shares have increased by 30.2% and is now trading at $4.23. View the best growth stocks for 2023 here. Are investors shorting Carisma Therapeutics? Carisma Therapeutics saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 2,580,000 shares, a decline of 8.5% from the August 31st total of 2,820,000 shares. Based on an average trading volume of 234,300 shares, the days-to-cover ratio is presently 11.0 days. Currently, 13.9% of the company's stock are sold short. View Carisma Therapeutics' Short Interest. When is Carisma Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our CARM earnings forecast. How were Carisma Therapeutics' earnings last quarter? Carisma Therapeutics, Inc. (NASDAQ:CARM) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.17. The company earned $3.56 million during the quarter. What is Carisma Therapeutics' stock symbol? Carisma Therapeutics trades on the NASDAQ under the ticker symbol "CARM." How do I buy shares of Carisma Therapeutics? Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Carisma Therapeutics' stock price today? One share of CARM stock can currently be purchased for approximately $4.23. How much money does Carisma Therapeutics make? Carisma Therapeutics (NASDAQ:CARM) has a market capitalization of $170.38 million and generates $40 million in revenue each year. The company earns $-19,880,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. How can I contact Carisma Therapeutics? Carisma Therapeutics' mailing address is 245 1st St Ste 1800, Cambridge, Massachusetts 02142-1292. The company can be reached via phone at 617-444-8550, via email at ir@sesenbio.com, or via fax at 617-858-0911. This page (NASDAQ:CARM) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.